concomitant disruption of adhesion. Therefore, rather "substrate-trapping" mutants of the SHPs should help to identify the proximal SHP-1 target(s) in these paththan acting as adhesion molecules themselves, PTPs such as PTP and PTP likely regulate the tyrosine ways. It also is unclear why SHP-1 appears to be recruited to cytokine receptors (e.g., the EPOR) substanphosphorylation and thus, the adhesive properties of cadherins. This may contribute to the mechanism by tially before dephosphorylation of Jaks is detected; a second event may be required to activate SHP-1. which cell-cell contact is stabilized and growth is inhibited in, for example, confluent cell cultures.
SHP-1 also regulates oligomeric receptor signaling. Activation through the B cell antigen receptor (BCR) is abrogated upon co-crosslinking of the inhibitory Fc Regulation of Growth Factor, Cytokine, and receptor (FcR), Fc␥RIIB; this serves to attenuate antiOligomeric Receptor Signaling by SHPs body production in the presence of circulating immune Nontransmembrane PTPs containing SH2 domains complexes. Mutation of a specific Fc␥RIIB tyrosyl resi-(SHPs) have been identified in species as diverse as due eliminates its ability to block B cell activation. A mammals, Xenopus and Drosophila. Two SHPs exist in phosphotyrosyl peptide comprising this sequence binds higher organisms. SHP-1 is expressed at highest levels SHP-1, a 70 kDa protein subsequently identified as in hematopoietic cells. The motheaten (me/me) mouse, SHP-2 and a 150 kDa protein, which may be the inositol caused by absence of SHP-1, provides a murine model monophosphatase SHIP (Ono et al., 1996) . Since me/me of SHP-1 deficiency. SHP-2, and its likely Drosophila mice were found to be refractory to Fc␥RIIB-mediated homolog Corkscrew (CSW), are expressed ubiquitously. inhibition, a model was proposed in which SHP-1 is a Whether an additional SHP exists in Drosophila or critical signaling molecule used by Fc␥RIIB to terminate whether, instead, CSW also subserves SHP-1 functions BCR signals. Interestingly, Fc␥RIIB engagement does remains to be determined.
not result in major changes in tyrosyl phosphorylation, The presence of SH2 domains in PTPs suggested suggesting that Fc␥RIIB-bound SHP-1 has a limited that these molecules might interact with known PTK number of targets (D'Ambrosio et al., 1995) . However, signaling pathways. Recent evidence, combining bio-SHP-1 is not generally required for Fc␥RIIB-mediated chemical and genetic approaches, validates this notion.
inhibition. Fc␥RIIB also blocks activation signals generPathways regulated by the two SHPs have been speciated through Fc⑀R, but Fc␥RIIB-mediated inhibition is fied, and several potential targets identified. Remarknormal in mast cells from me/me mice (Ono et al., 1996) . ably, despite their shared domain structure and considInstead, SHIP likely plays a key role in Fc␥RIIB signaling erable (55%) overall sequence identity, the SHPs appear in mast cells (Ono et al., 1996) . It is not clear whether to have distinct biological roles. Early studies indicated and/or why Fc␥RIIB uses distinct signaling pathways in that SHP-1 was predominantly a negative regulator of mast cells and B cells. Both SHIP and an SHP could be PTK signaling, whereas SHP-2 and CSW played a posinecessary for inhibition. Perhaps SHP-2 can substitute tive (i.e., signal enhancing) role. More recent work, alfor SHP-1 in mast cells but not B cells (Ono et al., 1996) . though not conclusive, raises the possibility that deAlternatively, the actions of SHP-1 and SHIP could conpending on the specific signaling pathway, SHPs may verge to produce similar effects, with different cell types have positive or negative effects. using predominantly one or the other.
SHP-1 Regulates Multiple Signaling Pathways
A motif similar to that in Fc␥RIIB, now termed the ITIM in Hematopoietic Cells (immune receptor tyrosine-based inhibitory motif), also The motheaten mouse displays a panoply of hematopoiis found in other receptors, notably killer-inhibitory reetic abnormalities, affecting virtually every lineage. It ceptors (KIRs) of NK cells and the B cell co-receptor now is clear that SHP-1 negatively regulates hematopoi-CD22. KIRs bind MHC class 1 antigens and prevent etic signaling pathways downstream of cytokine recepactivating receptors on NK cells from directing lysis of tors, oligomeric receptors, such as antigen and Fc rehost cells. SHP-1 is recruited to KIRs and phosphotyroceptors, and receptor tyrosine kinases (RTKs), syl peptides from the KIR ITIM activate SHP-1 in vitro. Upon EPO stimulation, cells expressing EPO receptor Furthermore, over-expression of a presumptive domimutants unable to recruit SHP-1 display prolonged tynant negative (C->S) mutant of SHP-1 blocks KIR-medirosyl phosphorylation of the receptor-associated PTK ated inhibition (Burshtyn et al., 1996) . However, since Jak2 and an enhanced mitogenic response (Klingmuller SHP-1, SHP-2 and SHIP all can bind to a similar motif et al., 1995). Likewise, interferon ␣-stimulated macro-(although with differing affinities), it is difficult to be cerphages from me/me mice exhibit markedly increased tain from these experiments that SHP-1 alone mediates tyrosyl phosphorylation of Jak 1, suggesting that one KIR signals. SHP-1 also binds tightly to CD22, and it general function of SHP-1 may be to inactivate Janus has been proposed that this interaction helps set the family PTKs (Jaks). However, not all Jaks (even those threshold for BCR activation (Doody et al., 1995) . This activated by the same cytokine receptor) are inactivated model is consistent with elegant genetic studies of mice by SHP-1, as interferon ␣-induced Tyk2 activation is expressing transgenic BCRs in the me/me background comparable in normal and me/me macrophages (David (Cyster and Goodnow, 1995) . However, it has not been et al., 1995). It is not clear whether SHP-2 or another demonstrated directly that CD22 ITIMs are required for PTP (perhaps an RPTP) substitutes for SHP-1 in these CD22-mediated inhibition. pathways. These studies are consistent with the hypoth-SHP-1 also binds to tyrosyl phosphorylated c-Kit and esis that SHP-1 regulates at least some cytokine recepbecomes tyrosyl phosphorylated in response to Kit litor-associated Jaks, but direct dephosphorylation of gand stimulation. Two groups crossed mice bearing kinase-defective mutants of c-Kit (W v /ϩ mice) with me/ϩ Jaks by SHP-1 has not been demonstrated. Use of novel mice, and the F1 progeny were intercrossed to generate provocative, no direct evidence for tyrosine phosphorylation of CTLA-4 has been presented; thus, the nature all possible allelic combinations of SHP-1 and c-Kit. The results indicate that SHP-1 negatively regulates c-Kit in of the proposed interaction between CTLA-4 and SHP-2 is unclear. Furthermore, it is not clear that the putative hematopoietic progenitors and that excess c-Kit signaling is an important contributor to the motheaten pheno-SHP-2 binding site is required for CTLA-4 function; notably, this site differs from other known high affinity bindtype (Lorenz et al., 1996; Paulson et al., 1996) . Again, however, SHP-1 does not negatively regulate c-Kit in all ing sites for SHP-2, all of which have isoleucine, valine, or leucine at the ϩ3 position. Thus, it is possible that cell types. These studies provide compelling genetic evidence for the importance of SHP-1 regulation of c-Kit SHP-2's interaction with CTLA-4 requires an intermediate protein. Most importantly, it is not clear whether the in vivo. Moreover, the tissue-specificity of this regulation emphasizes the complexity of the interplay between observed hyperactivation of T cell signaling components is the cause of the lymphoproliferation in CTLA-4 mice even a single RTK and PTP in the context of the whole organism.
as opposed to an indirect consequence of the increased number of activated T cells in these mice. A MAPK-dependent pathway linking changes in environin which CSW and DOS participate remain unclear. The mental stimuli to the onset of mitosis has been characstructure of DOS, which contains an N-terminal PH doterized in S. pombe. In this pathway the MAPK Spc1/ main and multiple potential tyrosine phosphorylation Sty1, the homolog of S. cerevisiae Hog1, is inactivated sites, is reminiscent of the mammalian proteins Gab1, by specific dephosphorylation of Y173 by the PTPs Pyp1 IRS-1 and IRS-2. Intriguingly, these proteins all bind and Pyp2 (Shiozaki and Russell, 1996; Wilkinson et al., SHP-2, and appear to serve as scaffolding proteins 1996). Spc1/Sty1 also is implicated in regulation of a downstream of mammalian receptor PTKs (RTKs), but distinct pathway in sexual development in response to the precise pathways that they regulate are not fully environmental stress (Shiozaki and Russell, 1996 ; Wilunderstood. Given their structure, one possibility is that kinson et al., 1996) . Spc1/Sty1 activation evokes the they collect secondary signaling molecules, which are stress-induced phosphorylation of the transcription facthen released by dephosphorylation so they may particitor Atf-1, which in turn is required for induction of meiotic pate in downstream signaling. It is not clear which downgenes. One such gene encodes Pyp2, which dephosphstream pathway(s) is(are) regulated by CSW and SHP-2.
Identification of a Presumptive
orylates Y173 of Spc1/Sty1 in a feedback inhibition loop. In the Sevenless pathway, CSW must be either upstream It is likely that analogous PTPs are involved in regulation and downstream of Raf or operate in a parallel pathway.
of some MAPK pathways in higher eukaryotes. Multiple studies in Xenopus and mammals have placed SHP-2 upstream of MAPK. Perhaps CSW and SHP-2 do Perspectives have multiple points of action in RTK signaling. AlternaTo understand fully the function of PTPs, it is necessary tively, SHP-2/CSW might not act directly on RTK signalto identify physiological substrates of the individual faming pathways, per se, but instead could function in a ily members. An approach to this problem has now been pathway that is permissive for RTK signaling, for examdeveloped, involving the use of "substrate-trapping" ple in response to attachment to ECM.
PTP mutants. Substrate trapping mutants retain similar SHP-2 as a Negative Regulator of T cell Signaling affinity for substrate to that of the wild type enzyme but SHP-2 associates with and may be responsible for inhibtheir catalytic activity is markedly reduced, to such an itory signals delivered through CTLA-4, a negative reguextent that an enzyme-substrate complex, once formed, lator of T cell activation (Marengere et al., 1996) . CTLA-4 is stable enough to withstand isolation and thus allow knockout mice display lymphoproliferation, with marked identification of the substrate. Mutant PTPs in which the increases in activated lymphocytes. SHP-2 co-immunocatalytically-essential, nucleophilic Cys residue from the precipitates with CTLA-4 and a phosphotyrosyl peptide signature motif has been mutated to Ser or Ala are inacderived from the CTLA-4 sequence (pY 201VKM) binds tive but in some cases retain the ability to bind to sub-SHP-2 in vitro, reportedly via SHP-2's SH2 domains. T strate in vitro. However, not all such mutant PTPs bind cells from lymph nodes of CTLA-4 knockout mice reveal stably to substrates in the cell. A novel substrate-trapmarked increases in Fyn, Lck, and ZAP-70 activity, sugping mutant has been developed in which the invariant gesting that recruitment of SHP-2 to CTLA-4 inactivates aspartate, which functions as a general acid to pro-TCR signaling as binding of SHP-1 to CD22 is proposed to inactivate BCR signals. PTP (Garton et al., 1996) . It is important to recognize Paulson, R.F., Vesely, S., Siminovitch, K.A., and Bernstein, A. (1996) .
that, in light of their potential to serve as substrate traps, Nature Genet. 13, 309-315.
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actually be functionally equivalent to dephosphorylation
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substrate affinity, as would be produced by altering the invariant Arg in the signature motif or a deletion mutant, would be more appropriate. Use of the Asp->Ala mutant has already illustrated a somewhat unexpected restricted substrate specificity of PTP-PEST for p130 cas , contradicting the generally accepted view that all PTPs are promiscuous (Garton et al., 1996) . Since this aspartate residue is invariant in PTP family members, such a strategy should be generally applicable to any PTP and may represent a powerful tool with which to delineate physiological substrates and function. Such novel biochemical approaches, combined with genetic analysis, should lead to rapid understanding of the biological function of PTPs.
